Abstract
BackgroundChimeric antigen receptor (CAR)-T cells are approved for use in the treatment of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) genetically modified autologous T cells expressing an anti-CD19...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have